Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sequence 4 Clear all
Completed Phase 1Phase 2 Interventional Results available

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753
View directory record Official record
Conditions
Tree Nut Allergy
Interventions
Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

NCT06167265
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol Tablet 100 mg, PMR Tablet 145 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

NCT02430545
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 12, 2026, 5:21 PM EDT
Completed No phase listed Observational

The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients

NCT01319630
View directory record Official record
Conditions
Severe Sepsis, Septic Shock, Microcirculation
Interventions
Sidestream Dark Field (SDF), Near Infrared Spectroscopy (NIRS)
Device
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Loperamide Grapefruit Juice Interaction PK Trial

NCT00806299
View directory record Official record
Conditions
Drug Interaction
Interventions
Loperamide / Red Grapefruit Juice, Loperamide/ White Grapefruit Juice, Loperamide / Pink Grapefruit Juice
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years to 59 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Not applicable Interventional

High Intensity Body-weight Circuit Training in Type 2 Diabetics

NCT04515992
View directory record Official record
Conditions
Type2 Diabetes
Interventions
High Intensity Body-weight Circuit Training (HIBC)
Behavioral
Lead sponsor
Kennesaw State University
Other
Eligibility
45 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 12, 2026, 5:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Neural Disorders

NCT02761707
View directory record Official record
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 12, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional

Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors

NCT04908709
View directory record Official record
Conditions
Malignant Brain Glioma
Interventions
Magnetic Resonance Spectroscopic Imaging, Proton Therapy
Procedure · Device
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00091299
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
warfarin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

NCT02792829
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 12, 2026, 5:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

NCT06262139
View directory record Official record
Conditions
MRI Scan
Interventions
MT218 injection
Drug
Lead sponsor
Songqi Gao
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

NCT02027454
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744, GSK1265744 matching placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

NCT05133830
View directory record Official record
Conditions
Pruritus
Interventions
Obeticholic acid, Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

NCT04606537
View directory record Official record
Conditions
Healthy, Drug Drug Interaction
Interventions
Itraconazole, Rifampin, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 2Phase 3 Interventional

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, HYQVIA
Biological
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 12, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional

Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients

NCT07455760
View directory record Official record
Conditions
Parkinson's Disease (PD), Essential Tremor
Interventions
Phoneme sequence learning, Cessation and re-enabling of stimulation of the STN, Cessation and re-enabling of stimulation of the VIM thalamic nucleus, Multisyllabic sequence learning
Behavioral · Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, Febuxostat XR Relative Bioavailability Study

NCT02504320
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR 80 mg Capsule F1, Febuxostat XR 80 mg Capsule F2, Febuxostat XR 80 mg Capsule F3, Febuxostat XR 80 mg Capsule F4
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 3 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

NCT00685425
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

NCT07093008
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
Drug
Lead sponsor
AQILION AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 12, 2026, 5:21 PM EDT
Recruiting Phase 3 Interventional

CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial

NCT06027099
View directory record Official record
Conditions
Chronic Pain, Back Pain, Neck Pain, Opioid Misuse
Interventions
Tizanidine, MI-Opioid Taper, Placebo, Enhanced Usual Care
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Stanford, California • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

NCT05383508
View directory record Official record
Conditions
Nicotine Vaping, Nicotine, Vaping
Interventions
CA35, CM35, Cig
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
24 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 12, 2026, 5:21 PM EDT
Recruiting Phase 2 Interventional

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

NCT06559826
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

NCT07025577
View directory record Official record
Conditions
Healthy Participants
Interventions
Immunoglobulin G
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 12, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Different Forms of TAK-994 in Healthy Adults

NCT04745767
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-994
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 12, 2026, 5:21 PM EDT